Boston Scientific (BSX) – Analysts’ Recent Ratings Changes

Boston Scientific (NYSE: BSX) has recently received a number of price target changes and ratings updates:

  • 1/16/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
  • 1/10/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $32.00 price target on the stock.
  • 1/9/2018 – Boston Scientific was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry.”
  • 1/5/2018 – Boston Scientific was upgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “top pick” rating.
  • 1/3/2018 – Boston Scientific is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $27.00 price target on the stock.
  • 12/12/2017 – Boston Scientific had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $32.00 price target on the stock.
  • 12/8/2017 – Boston Scientific was upgraded by analysts at Needham & Company LLC from a “buy” rating to a “strong-buy” rating. They now have a $32.00 price target on the stock, up previously from $25.04.
  • 12/7/2017 – Boston Scientific was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating.
  • 12/4/2017 – Boston Scientific was given a new $33.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 11/30/2017 – Boston Scientific was given a new $31.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 11/30/2017 – Boston Scientific was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $31.00 price target on the stock.
  • 11/29/2017 – Boston Scientific had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $31.00 price target on the stock.
  • 11/29/2017 – Boston Scientific had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 11/29/2017 – Boston Scientific had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/29/2017 – Boston Scientific had its price target lowered by analysts at Canaccord Genuity from $36.00 to $35.00. They now have a “buy” rating on the stock.

Boston Scientific Corporation (BSX) opened at $26.98 on Wednesday. The firm has a market capitalization of $37,050.00, a P/E ratio of 44.23, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.27 earnings per share. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $28.42, for a total transaction of $440,510.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total value of $139,104.00. Following the transaction, the senior vice president now directly owns 38,116 shares in the company, valued at approximately $1,029,132. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,585 shares of company stock worth $2,578,197. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.